Your browser is no longer supported. Please, upgrade your browser.
Settings
ADAP [NASD]
Adaptimmune Therapeutics plc
Index- P/E- EPS (ttm)-1.00 Insider Own0.10% Shs Outstand156.10M Perf Week-12.04%
Market Cap547.35M Forward P/E- EPS next Y-0.99 Insider Trans-5.28% Shs Float126.69M Perf Month-34.55%
Income-155.80M PEG- EPS next Q-0.27 Inst Own73.00% Short Float2.46% Perf Quarter-27.53%
Sales6.20M P/S88.28 EPS this Y30.10% Inst Trans-0.02% Short Ratio1.60 Perf Half Y-22.34%
Book/sh1.54 P/B2.32 EPS next Y-2.00% ROA-38.80% Target Price9.17 Perf Year-20.44%
Cash/sh1.57 P/C2.28 EPS next 5Y1.00% ROE-53.30% 52W Range3.37 - 7.34 Perf YTD-33.58%
Dividend- P/FCF- EPS past 5Y-24.90% ROI-39.10% 52W High-51.23% Beta1.93
Dividend %- Quick Ratio7.30 Sales past 5Y-15.10% Gross Margin- 52W Low6.23% ATR0.29
Employees462 Current Ratio7.30 Sales Q/Q0.00% Oper. Margin- RSI (14)27.45 Volatility7.29% 7.12%
OptionableYes Debt/Eq0.00 EPS Q/Q-18.60% Profit Margin- Rel Volume0.52 Prev Close3.73
ShortableYes LT Debt/Eq0.00 EarningsNov 04 BMO Payout- Avg Volume1.95M Price3.58
Recom2.70 SMA20-20.33% SMA50-28.02% SMA200-25.85% Volume1,021,148 Change-4.02%
May-28-21Initiated Barclays Underweight $4
Apr-22-20Initiated Mizuho Neutral $3
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-31-19Initiated ROTH Capital Buy
May-30-19Resumed Citigroup Buy
May-07-19Downgrade SVB Leerink Outperform → Mkt Perform $12 → $5
Mar-17-17Initiated Wells Fargo Market Perform
Oct-24-16Downgrade BofA/Merrill Neutral → Underperform
Sep-30-16Initiated Raymond James Outperform $16
Feb-25-16Initiated Citigroup Buy $15
Jun-01-15Initiated Leerink Partners Outperform $24
Jun-01-15Initiated Guggenheim Buy
Jun-01-15Initiated BofA/Merrill Neutral
Dec-03-21 04:25AM  
Dec-01-21 03:27PM  
Nov-18-21 10:00AM  
Nov-12-21 07:00AM  
Nov-11-21 09:00AM  
Nov-04-21 04:00PM  
07:30AM  
Oct-21-21 08:00AM  
Oct-16-21 07:00AM  
Oct-05-21 08:00AM  
Oct-04-21 06:09AM  
Sep-27-21 10:08AM  
Sep-24-21 08:52AM  
Sep-17-21 04:48PM  
Sep-13-21 09:50AM  
07:00AM  
Sep-08-21 11:39AM  
10:55AM  
Sep-07-21 02:32PM  
10:16AM  
09:08AM  
07:00AM  
03:52AM  
Sep-06-21 10:48AM  
Sep-05-21 06:15AM  
Aug-23-21 01:38PM  
Aug-16-21 10:05AM  
Aug-09-21 06:30PM  
04:00PM  
Aug-05-21 01:07AM  
Jul-28-21 08:11AM  
Jul-19-21 10:00AM  
Jun-21-21 10:00AM  
Jun-06-21 03:01AM  
May-20-21 05:49PM  
10:15AM  
May-19-21 05:00PM  
May-11-21 12:32PM  
08:00AM  
May-06-21 07:30AM  
Apr-27-21 04:30PM  
Apr-22-21 08:00AM  
Apr-07-21 01:09AM  
Feb-25-21 07:30AM  
06:15AM  
Feb-11-21 08:00AM  
Feb-06-21 01:03AM  
Dec-16-20 12:32PM  
Dec-07-20 11:32PM  
Nov-20-20 07:30AM  
Nov-19-20 09:00AM  
Nov-12-20 08:00AM  
Nov-09-20 03:18PM  
Nov-08-20 10:00AM  
Nov-06-20 11:01AM  
Nov-05-20 07:30AM  
06:15AM  
Oct-22-20 08:00AM  
Oct-16-20 12:41PM  
Oct-15-20 04:40PM  
Oct-13-20 12:04PM  
Oct-09-20 06:18AM  
Aug-28-20 10:30AM  
Aug-11-20 12:00PM  
Aug-10-20 07:40AM  
07:25AM  
Aug-06-20 07:30AM  
Jul-23-20 04:00PM  
Jul-22-20 08:00AM  
Jul-05-20 02:25PM  
Jun-23-20 11:26AM  
Jun-17-20 09:33AM  
08:52AM  
Jun-12-20 06:30AM  
Jun-08-20 10:30AM  
Jun-04-20 10:45AM  
Jun-02-20 04:37AM  
12:38AM  
Jun-01-20 09:39PM  
12:51PM  
11:01AM  
09:38AM  
06:09AM  
06:00AM  
04:15AM  
May-29-20 05:08PM  
02:20PM  
10:32AM  
10:24AM  
07:30AM  
May-19-20 07:02AM  
May-14-20 12:00PM  
08:55AM  
07:30AM  
May-12-20 08:00AM  
06:07AM  
Apr-29-20 08:00AM  
Apr-28-20 12:00PM  
08:00AM  
Mar-20-20 10:40PM  
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rawcliffe AdrianChief Executive OfficerSep 01Sale5.202,78214,4523,070Sep 01 09:00 PM
Lunger JohnChief Patient Supply OfficerAug 02Sale3.582,93910,5364,873Aug 02 05:09 PM
Rawcliffe AdrianChief Executive OfficerJun 28Sale4.372,79412,2103,058Jun 28 09:01 PM
Alleva Lawrence MDirectorJun 01Buy0.7912,6009,95412,600Jun 03 04:31 PM
TAYTON-MARTIN HELEN KATRINAChief Business OfficerMar 03Option Exercise0.161,785,000280,2451,800,000Mar 03 09:01 PM
Lunger JohnChief Patient Supply OfficerJan 19Sale5.674,35824,7087,346Jan 19 09:01 PM
Norry ElliotChief Medical OfficerJan 19Sale5.672,11111,9683,539Jan 19 09:01 PM
Rawcliffe AdrianChief Executive OfficerJan 19Sale5.679,87956,00913,529Jan 19 09:00 PM
Lunger JohnChief Patient Supply OfficerJan 12Sale6.151,0586,5091,767Jan 12 09:01 PM
Bertrand William C JRChief Operating OfficerJan 12Sale6.152,23413,7443,768Jan 12 09:01 PM
Rawcliffe AdrianChief Executive OfficerJan 12Sale6.152,70716,6543,695Jan 12 09:00 PM
Norry ElliotChief Medical OfficerJan 12Sale6.158415,1741,396Jan 12 09:00 PM
Bertrand William C JRChief Operating OfficerJan 04Sale5.333,49918,6425,864Jan 05 09:01 PM
Lunger JohnChief Patient Supply OfficerJan 04Sale5.331,0655,6741,760Jan 05 09:02 PM
Norry ElliotChief Medical OfficerJan 04Sale5.338454,5021,392Jan 05 09:00 PM
Rawcliffe AdrianChief Executive OfficerJan 04Sale5.334,96726,4646,737Jan 05 09:00 PM
Wood GavinChief Financial OfficerDec 14Buy0.6924,00016,55057,000Dec 16 09:00 PM
Bertrand William C JRChief Operating OfficerDec 14Buy0.69207,000143,824284,808Dec 15 09:00 PM